Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse

NCT00704288 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT00704288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00704288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse
Lead sponsor
Exelixis
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
December 31, 2012
Enrollment
222 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme